Altesa BioSciences Unveils Promising Vapendavir Results at ASM Microbe Conference
Altesa BioSciences presented new findings from a Phase 2a challenge study of vapendavir at the 2026 American Society for Microbiology (ASM) Microbe Conference. Vapendavir, an investigational oral rhinovirus capsid inhibitor, showed a reduction in inflammatory response and viral load in COPD patients infected with rhinovirus. The study results suggest that vapendavir could reduce the severity and duration of illness compared to placebo. Rhinovirus is a major cause of acute exacerbations in COPD, contributing to increased morbidity and mortality. The company has also initiated the Phase 2b CARDINAL clinical trial to further evaluate vapendavir's efficacy in improving respiratory symptoms and maintaining lung function in COPD patients. 
